Alverno is the first laboratory in the Midwest
region of the United States to deploy AI in routine practice to
improve the quality of care for its community.
Alverno Laboratories, a provider of high-quality
diagnostic testing services and one of the largest integrated
laboratory networks in the United States, and Ibex Medical
Analytics, the leader in artificial intelligence (AI)-powered
cancer diagnostics, today announced the launch of the Ibex’s AI
platform in routine practice within Alverno’s laboratory network in
Illinois and Indiana. The phased launch encompasses AI-centric
solutions for cancer diagnosis across multiple tissue types,
including prostate, breast and gastric, that support pathologists
and other physicians in providing the utmost quality of care for
their patients. The laboratory system has recently completed phase
1 of its launch plan, enabling AI-powered prostate cancer detection
for prostate biopsies, followed by breast and gastric.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240618330624/en/
Alverno serves over 30 hospital laboratories and thousands of
physician offices and other care facilities, touching over 8
million patients’ lives per year across the Midwest. Alverno was
also among the first laboratories in the United States to digitize
its pathology services, harnessing the high-throughput capabilities
of the Philips IntelliSite Pathology Solution across its system.
The combined power of digital pathology and AI levels up the
services provided by Alverno to hospitals, physicians, patients and
caregivers by improving diagnostic accuracy and turnaround
time.
“When looking for an AI partner, we wanted a shared vision for
innovation yet a relentless drive for execution. We chose Ibex
because of its high-quality, innovative products and customer
service. Throughout our implementation and onboarding process, the
Ibex team was active and responsive, something not always
experienced when working on new projects,” said Sam Terese, CEO and
President of Alverno Laboratories. “For us, the notion of going
digital with AI is just something we would do, it's about who we
are. It's about delivering appropriate and great care to our
patients while speeding up time to results and ensuring the highest
possible quality result any lab can deliver, and we are really
thrilled to have a partnership with Ibex to help us along in that
journey.”
Ibex’s suite of solutions supports Alverno pathologists in a
variety of tasks during routine review of prostate, breast and
gastric biopsies. The solutions help with case prioritization,
AI-powered cancer detection and reporting and optimization of
immunohistochemistry workflows and other productivity-enhancing
tools. This implementation of AI on a large scale across the entire
laboratory network has the potential to improve pathologists’
productivity and user experience, reduce operational costs and
improve overall service levels. Ibex is the most widely deployed AI
technology in pathology and is used as part of everyday clinical
practice at laboratories, hospitals and health systems worldwide.
Ibex demonstrated outstanding outcomes across multiple clinical
studies performed on various tissue types and diagnostic
workflows.1,2,3,4,5
“Alverno has a very clear commitment to innovation and
continually improving the delivery of care for its community, and
this commitment is demonstrated by the successful implementation of
the Ibex’s suite of solutions,” said Joseph Mossel, CEO and
Co-founder of Ibex Medical Analytics. “AI enables Alverno
pathologists to work more consistently, reproducibly and
efficiently to enable the highest level of diagnostic laboratory
services for the patients in the community for which they serve.
We're honored and excited to partner with their team and support
them in providing the highest quality of diagnostic services."
For additional information on Alverno Laboratories, please visit
alvernolabs.com and LinkedIn. For additional information on Ibex
Medical Analytics, please visit ibex-ai.com, LinkedIn and X.
About Alverno Laboratories
Alverno Laboratories, located in Hammond, IN, provides clinical
and anatomic pathology services and testing to communities
throughout Illinois and Indiana. Alverno’s focus is providing the
best patient care utilizing advanced technologies such as digital
pathology, AI, Precision Medicine/Next-Gen Sequencing and complex
automation. As a joint venture between Franciscan Alliance and
Ascension Illinois, Alverno Laboratories operates over 30 hospital
laboratories and provides laboratory testing to over 2,500
physician offices, freestanding urgent care facilities, and
research organizations. Innovation is at the center of laboratory
operations as demonstrated by the acquisition of one of the largest
digital pathology networks in the country. Digital pathology,
coupled with artificial intelligence technology, will decrease
turnaround times of oncology cases and enhance outcomes. Advanced
automation in microbiology rapidly increases the diagnosis of
bloodborne infections that can lead to sepsis.
About Ibex Medical Analytics
Ibex Medical Analytics is transforming cancer diagnostics with
world-leading clinical grade AI-powered solutions for pathology.
Empowering physicians and supporting pathologists, Ibex is on a
mission to provide accurate, timely and personalized cancer
diagnosis for every patient. Ibex is the first and most widely
deployed AI-powered platform in pathology. Pathologists worldwide
use Ibex as part of their everyday routine to improve the accuracy
of cancer diagnosis, implement comprehensive quality control
measures, reduce turnaround times, and boost productivity with more
efficient workflows.
The Ibex suite includes solutions which are for Research Use
Only (RUO) in the United States and not cleared by the FDA.
Multiple solutions are CE marked (IVDD and IVDR) and registered
with the UK MHRA. For more information, including indication for
use and regulatory approval in other countries, contact Ibex
Medical Analytics.
[1] Pantanowitz et al., “An Artificial Intelligence Algorithm
for Prostate Cancer Diagnosis in Whole Slide Images of Core Needle
Biopsies: A Blinded Clinical Validation and Deployment Study,” The
Lancet Digital Health (Aug 2020)
[2] Sandbank et al., “Validation and Real-World Clinical
Application of an Artificial Intelligence Algorithm for Breast
Cancer Detection in Biopsies,” npj Breast Cancer 8, 129 (2022)
[3] Comperat et al., “Clinical Level AI-Based Solution for
Primary Diagnosis and Reporting of Prostate Biopsies in Routine
Use: A Prospective Reader Study, European Congress of Pathology
(2021)
[4] Raoux et al., “Novel AI-Based Solution for Supporting
Primary Diagnosis of Prostate Cancer Increases the Accuracy and
Efficiency of Reporting in Clinical Routine,” USCAP (2021)
[5] Sandbank et al., “Validation and Clinical Deployment of an
AI-Based Solution for Detection of Gastric Adenocarcinoma and
Helicobacter pylori in Gastric Biopsies,” USCAP (2022)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618330624/en/
Abby Ramsay Greenough Communications
aramsay@greenoughagency.com